899503

FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB NUMBER:	3235-0076			
Expires:	April 30, 2008			
Estimated average burde	en			
hours per response	16.00			

FORM D		 		
NOTICE OF SALE OF SECURITIES PURSUANT TO	SEC USE ONLY			
REGULATION D, SECTION 4(6), AND/OR			Seri	al
UNIFORM LIMITED OFFERING EXEMPTION	DATE RECEIVED			
Name of Offering (□ check if this is an amendment and name has changed, and indicate change.)				
Common Stock			PERCINE 2	<u> </u>
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ Section	4(6) □ UL	OE	-921120	2
Type of Filing: ■ New Filing □ Amendment		A 5.	EP 20 2005	C.
A. BASIC IDENTIFICATION DATA	4			
Enter the information requested about the issuer			100	
Name of Issuer (□ check if this is an amendment and name has changed, and indicate change.)				MIOCES
Boston Life Sciences, Inc.	يها . نون	. حدير. بجديثان		- 622 : - 0000
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telepho	ne Number (Incl	uding Area Code)	05/ 23 9
20 Newbury Street, 5th floor, Boston, MA 02116	617-425	i-0200		Tong
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices)	Telepho	ne Number (Incl	uding Area Code)	
Brief Description of Business:				
development stage biotechnology company engaged in the research and development of novel thera diseases and cancer.	peutic and	diagnostic solut	tions for central ne	rvous system
Type of Business Organization				
■ corporation ☐ limited partnership, already formed	□ other	(please specif	1 11 1 100 1101 1 500 1101 1 500	
□ business trust □ limited partnership, to be formed				
Month Year Actual or Estimated Date of Incorporation or Organization 10 92 ■ Actual □ Estimated Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: (C) for Connecting Post of the foreign instinction)			05067	

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not tate exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENTI	IFICATION DATA			
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 						
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
G						
Savas, Peter G. Business or Residence Address	(Number and S	treet, City, State, Zip Coo	de)			
Dushiess of Residence Address	(14dinber and 5	duct, erry, state, zap eod	10)			
c/o Boston Life Sciences, Inc., 20 Newbu	ary Street, 5th flo	oor, Boston, MA 02116				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Pykett, Mark J.						
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	ie)			
c/o Boston Life Sciences, Inc., 20 Newbu Check Box(es) that Apply:			- 5 005	- B:		
Full Name (Last name first, if individual)	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner	
Tun Name (Last name mst, ii morvioual)						
Rice, Jr., Kenneth L.						
Business or Residence Address	(Number and St	reet, City, State, Zip Cod	e)			
c/o Boston Life Sciences, Inc., 20 Newbu	ury Street 5th flo	or Roston MA 02116				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)		E Donollotti O Wiles	E EMOCRATIC OTTION	<u> </u>	El conordi uno or managing i armer	
Langer, Robert Business or Residence Address	(Number and St	reet, City, State, Zip Cod	۵۱			
Dusiness of Residence Address	(Ivalinoe) and Si	ice, city, state, zip cou	<i>c)</i>			
c/o Boston Life Sciences, Inc., 20 Newbu	ry Street, 5th flo	oor, Boston, MA 02116				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Mullen, Michael J.				a.		
Business or Residence Address (Number and Street, City, State, Zip Code)						
J. B. A I'M. C I . AAN I	. C	D 344 00116				
c/o Boston Life Sciences, Inc., 20 Newby Check Box(es) that Apply:	Promoter □	Beneficial Owner	☐ Executive Officer	■ Director	Consol and/or Managing Portner	
Full Name (Last name first, if individual)	Li Fioliotei	D Belleticial Owliet	LI Executive Officer	Director	☐ General and/or Managing Partner	
Tun vane (223) name mai, n mai vidua)						
Preston, John T.			<u> </u>			
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)			
c/o Boston Life Sciences, Inc., 20 Newbu	ry Street, 5 th flo	or, Boston, MA 02116				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Cincon Dobout I						
Gipson, Robert L. Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
Dames of Residence Hadress	(. vanioer and c	oreer, erry, orace, 22p eo	dc)			
c/o Ingalls & Snyder LLC, 61 Broadway, New York, NY 10006						
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Business or Residence Address	(Number and S	Street, City, State, Zip Co.	de)			

B. INFORMATION ABOUT OFFERING							
		Yes	No				
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?						
	Answer also in Appendix, Column 2, if filing under ULOE.						
2.	What is the minimum investment that will be accepted from any individual?	\$ <u>n/a</u>					
3.	Does the offering permit joint ownership of a single unit?	Yes	No				
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or	=					
	similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.						
Full Non	Name (Last name first, if individual) e.						
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	ne of Associated Broker or Dealer		 				
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	(Check "All States" or check individual States)	All States					
_ [/ _ [] _ [] _ []	[L] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				
Full	name (Last name first, if individual)						
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	e of Associated Broker or Dealer						
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	(Check "All States" or check individual States)	All States					
_ {A		_ [HI]	_ [ID]				
_ [I		_ [MS] _ [OR]	_ [MO]				
_ []		_ [WY]	_ [PA] _ [PR]				
Full	Name (Last name first, if individual)						
Busin	ness or Residence Address (Number and Street, City, State, Zip Code)						
Nam	e of Associated Broker or Dealer						
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers						
	All States						
_ [A _ [1] _ [N _ [F	L] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]				

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold	
	Type of Security			
	Debt	\$	\$	
	Equity	\$ <u>12,780,000</u>	\$ <u>12,780,000</u>	
	■ Common □ Preferred			
	Convertible Securities (including warrants)	\$	\$	
	Partnership Interests	\$	\$	
	Other (Specify)	\$	\$	
	Total	\$ 12,780,000	\$ _12,780,000	
	Answer also in Appendix, Column 3, if filing under ULOE.			
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases	
	Accredited Investors			
	Non-accredited Investors		\$	
	Total (for filings under Rule 504 only)		\$	
	Answer also in Appendix, Column 4, if filing under ULOE	×.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold	
	Rule 505		\$ _	
	Regulation A		\$	
	Rule 504		\$	
	Total		\$	
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.			
	Transfer Agent's Fees	ם	\$	
	Printing and Engraving Costs		\$	
	Legal Fees		\$ 20,000	
	Accounting Fees		\$	
	Engineering Fees		\$	
	Sales Commissions (specify finders' fees separately)		\$	
	Other Expenses (identify)	0	\$	
			\$ 20,000	
	Total		Ψ	

	C. OFFERIN	G PRICE, NUMBER OF INVESTORS, EXP	ENSES AN	D USE OF PROCEEDS		
	 b. Enter the difference between the aggregate offering price given in response to Part C – Que 1 and total expenses furnished in response to Part C – Question 4.a. This difference is the "adjusted gross proceeds to the issuer." 				\$	12,760,000
5.	for each of the purposes shown. If the ame and cheek the box to the left of the estimate	gross proceeds to the issuer used or proposed to bount for any purpose is not known, furnish an est e. The total of the payments listed must equal that in response to Part C – Question 4.b above.	imate			
				Payments to Officets, Directors, & Affiliates		Payments To Others
	Salaries and fees		O	S	а	S
	Purchase of real estate			S	D	<u> </u>
	Purchase, rental or leasing and installation	of machinery and equipment	ניז	\$	1:3	\$
	Construction or leasing of plant buildings a	and facilities	D	\$	a	S
		c value of securities involved in this offering				
	that may be used in exchange for the assets or securities of another issuer pursuant to a merger)			\$	១	S
	Repayment of indebtedness	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ם	Š	13	\$
	Working capital			S		S_12,760,000
	Other (specify):		n	\$	 	<u></u>
			С	\$	Ð	¢
	Column Totals			S 0	=	S 12,760,000
	Total Payments Listed (column totals added)		•	· · · · · · · · · · · · · · · · · · ·		
				5 3 12	,760,000 	
		ð, federal signatul	RE			
an t	issuer has duly caused this notice to be sign indertaking by the issuer to furnish to the U.S -accredited investor pursuant to paragraph (b	ed by the undersigned duly authorized person. If i. Securities and Exchange Commission, upon w.)(2) of Rule 502.	ritten reque	is filed under Rule 505, the l st of its staff, the information	following : furnished	signature constitutes by the issuer to any
Issu	er (Print or Type)	Signature	,: ·	Date		
	ton Life Sciences, Inc.	S. C.		September 8, 2005		
Nai	nc of Signer (Print or Type)	Title of Signer (Print or Type)				
	meth L. Rice, Jr.	Chief Financial Officer				
						